A Safety Study of SGN-CD19A for B-Cell Lymphoma

• Status: Completed
• Trial end date: 2017-02-16
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.
• Treatments: Antibodies

Criteria

Inclusion Criteria:

• Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade 3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology, Burkitt lymphoma, or B-lineage lymphoblastic lymphoma

• Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received intensive salvage therapy.

• Eastern Cooperative Oncology Group status of 0 or 1

• Measurable disease

Exclusion Criteria:

• Allogeneic stem cell transplant (SCT)